{"id":752944,"date":"2023-05-01T08:18:14","date_gmt":"2023-05-01T12:18:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/"},"modified":"2023-05-01T08:18:14","modified_gmt":"2023-05-01T12:18:14","slug":"ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/","title":{"rendered":"Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WALTHAM, Mass., May  01, 2023  (GLOBE NEWSWIRE) &#8212; Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the efficacy and safety of IBSRELA will be presented in a poster at the 2023 Digestive Disease Week Conference (DDW 2023) to be held May 6-9, 2023, in Chicago, Illinois.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"text-align: left;vertical-align: middle;vertical-align: top\">Title: <strong>Analysis of Patient-Reported Treatment Satisfaction and Abdominal Pain Score in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) Treated with Tenapanor\u00a0<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:18%;width:18%;min-width:18%;text-align: left;vertical-align: middle;vertical-align: top\">Authors:\u00a0\u00a0<\/td>\n<td style=\"max-width:82%;width:82%;min-width:82%;text-align: left;vertical-align: middle;vertical-align: top\">Anthony Lembo, Darren M. Brenner, Brian E. Lacy, Suling Zhao, <br \/>Susan Edelstein, David P. Rosenbaum<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Abstract Number:<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">3831977<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Poster Number:<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Tu1618<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">Date\/Time:\u00a0\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">May 9, 2023, from 12:30 PM to 1:30 PM CDT\u00a0(UTC \u20135)<\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>In addition to the poster presentation during DDW, Ardelyx is sponsoring a Product Theater titled: <em>Discover a Different Mechanism of Action to Treat Adults with IBS-C: A Case Based Discussion, <\/em>on May 8, 2023, from 9:30-10:15am CT, where Darren Brenner, M.D., Professor of Medicine and Surgery, Northwestern University Feinberg School of Medicine, will review the multifactorial pathophysiology of IBS-C, the novel mechanism of action of IBSRELA, and efficacy and safety data of IBSRELA from the Phase 3 clinical trial program. Dr. Brenner will also review two patient cases and discuss treatment decisions in IBS-C.<\/p>\n<p>\n        <strong>INDICATION <\/strong><br \/>\n        <br \/>IBSRELA (tenapanor) 50mg BID is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.<\/p>\n<p>\n        <strong>IMPORTANT<\/strong><br \/>\n        <strong>SAFETY<\/strong><br \/>\n        <strong>INFORMATION<\/strong>\n      <\/p>\n<p>\n        <strong>WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS<\/strong>\n      <\/p>\n<p>\n        <strong>IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.<\/strong>\n      <\/p>\n<p>\u00a0<\/p>\n<p>\n        <strong>CONTRAINDICATIONS<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.<\/li>\n<li>IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.<\/li>\n<\/ul>\n<p>\n        <strong>WARNINGS AND PRECAUTIONS<\/strong><br \/>\n        <br \/>\n        <strong>Risk of Serious Dehydration in Pediatric Patients<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).<\/li>\n<li>Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.<\/li>\n<\/ul>\n<p>\n        <strong>Diarrhea <\/strong><br \/>\n        <br \/>Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients. If severe diarrhea occurs, suspend dosing and rehydrate patient.<\/p>\n<p>\n        <strong>MOST COMMON ADVERSE REACTIONS <\/strong><br \/>\n        <br \/>The most common adverse reactions in IBSRELA-treated patients (incidence \u22652% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs &lt;1%), flatulence (3% vs 1%) and dizziness (2% vs &lt;1%).<\/p>\n<p>\n        <strong>Please see full <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IF0SO_dy5o-bK2QcF3f0T4dI36EQpUsByunJFHRSfjEfFwYHT9vurto8ewo6BWk_eTBcgrnpjKwvu_1dEx-LNKMEhEOu0KB-JZhcIlJlH0F5B66Cw45T7B_wD8Gt1ZdS4tfKDaXPBmVEehgPoalZcnuad7MqJGklVvAk9YaR3tX5rYZZ469XRx3hVplxPEki\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong>Prescribing Information<\/strong><br \/>\n        <\/a><br \/>\n        <strong>, including Boxed Warning, for additional risk information.<\/strong>\n      <\/p>\n<p>\n        <strong>About Irritable Bowel Syndrome with Constipation (IBS-C)<\/strong><br \/>\n        <br \/>Irritable bowel syndrome with constipation (IBS-C) is a gastrointestinal disorder characterized by both abdominal pain and altered bowel movements, estimated to affect 12 million people in the US. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden.<\/p>\n<p>\n        <strong>About IBSRELA for IBS-C<\/strong><br \/>\n        <br \/>IBSRELA (tenapanor) is a locally acting inhibitor of the sodium\/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium. By inhibiting NHE3 on the apical surface of the enterocytes, tenapanor reduces absorption of sodium from the small intestine and colon, thus retaining luminal water content, which accelerates intestinal transit time and results in a softer stool consistency. IBSRELA has also been shown to reduce abdominal pain by decreasing visceral hypersensitivity and by decreasing intestinal permeability in animal models. In a rat model of colonic hypersensitivity, tenapanor reduced visceral hyperalgesia and normalized colonic sensory neuronal excitability.<\/p>\n<p>\n        <strong>About Ardelyx, Inc.<\/strong><br \/>\n        <br \/>Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx\u2019s first approved product, IBSRELA\u00ae (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH\u00ae (tenapanor), a novel product candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and\/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=i051aqdT3M15QnMSEviRXttg8A-c8sU4pyIJNUw_pnC7IuvyWlFw65kXawRbn2tlnMwqDvmDN4AhPTBkx3jrMg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/ardelyx.com\/<\/a> and connect with us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3pykexVEwhAwoolrOjSF9Doln0LVoq4cnwlXoyl3DfddBoPWYpVCaeIv2jR81cv_rg1jrspqDyyHbYGYvlSpOw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nIf-Wk0sU5m-pa4_ur_pDWtE4qo2f1-YJvFoxdflU0YaAARN_drcVcPKrUgoCX-Po8yiPl6WQffjepxDrYgQT560GgLl_DRR2BsRn5UdypejCQx2QlNrihQWcnXisBxFnvrjGlrv69DnrQ7Cvt5qmcLHYbHJ_C4Tu-l2MloWrYaC0kjvN43haFRi2EPsOqF1yWwjQBpGsd0BkaSw_hpPoYGaXnoOyDsv9oI71oK05q6ZAMsAzz3InYr5I9YC2iObJriU0onFpNTdwszB4Wwc4iFOenXruJ_pr1zfqVZUX78yGOB6g3mZs-FNo9nri77HGtqdIf2u8AZzvny-tQTaQg==\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BUb4f2vJSsmfJNwD7uxs_1eVp2NkXl0ANYbHCeR__vAXwo8_hztU_0p2GHAGOab8aX-WEgrT482wMkwlActmOA==\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>\n        <strong>Investor and Media Contacts: <\/strong><br \/>\n        <br \/>Caitlin Lowie<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=U9wqaKC80wyN4uhHPuVGX8XchwAieULEw6Y9chvlMsqsNoiqHE3Y00XD0ci5xrkh_qrrSTvnA8kDLpMBfNE1PJXKYhuaFSgHKPRtDeFiFBw=\" rel=\"nofollow noopener\" target=\"_blank\">clowie@ardelyx.com<\/a><\/p>\n<p>Kimia Keshtbod <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CtFz-UWtbT9hlDUAOMgXcNNL1JUy3hsPwa43xz8iCDnTjDTt-ZXOaOr8-VhhU1_pKQe6QWJXzlx4Vdq8BJLrAUHJ0fcD7f96AjhXZanKzw0=\" rel=\"nofollow noopener\" target=\"_blank\">kkeshtbod@ardelyx.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODMyMSM1NTY0ODgxIzIwMDU0MDg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTdjNzI4Y2EtYzMyYi00Njc5LWE5MWQtOTZiMGU0ZmJhNzJlLTEwMTY5ODE=\/tiny\/Ardelyx-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) &#8212; Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the efficacy and safety of IBSRELA will be presented in a poster at the 2023 Digestive Disease Week Conference (DDW 2023) to be held May 6-9, 2023, in Chicago, Illinois. Title: Analysis of Patient-Reported Treatment Satisfaction and Abdominal Pain Score in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) Treated with Tenapanor\u00a0 Authors:\u00a0\u00a0 Anthony Lembo, Darren M. Brenner, Brian E. Lacy, Suling Zhao, Susan Edelstein, David P. Rosenbaum Abstract Number: 3831977 Poster Number: Tu1618 Date\/Time:\u00a0\u00a0 May 9, 2023, from 12:30 PM &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-752944","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) &#8212; Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the efficacy and safety of IBSRELA will be presented in a poster at the 2023 Digestive Disease Week Conference (DDW 2023) to be held May 6-9, 2023, in Chicago, Illinois. Title: Analysis of Patient-Reported Treatment Satisfaction and Abdominal Pain Score in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) Treated with Tenapanor\u00a0 Authors:\u00a0\u00a0 Anthony Lembo, Darren M. Brenner, Brian E. Lacy, Suling Zhao, Susan Edelstein, David P. Rosenbaum Abstract Number: 3831977 Poster Number: Tu1618 Date\/Time:\u00a0\u00a0 May 9, 2023, from 12:30 PM &hellip; Continue reading &quot;Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-01T12:18:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODMyMSM1NTY0ODgxIzIwMDU0MDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference\",\"datePublished\":\"2023-05-01T12:18:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/\"},\"wordCount\":904,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODMyMSM1NTY0ODgxIzIwMDU0MDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/\",\"name\":\"Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODMyMSM1NTY0ODgxIzIwMDU0MDg=\",\"datePublished\":\"2023-05-01T12:18:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODMyMSM1NTY0ODgxIzIwMDU0MDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODMyMSM1NTY0ODgxIzIwMDU0MDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/","og_locale":"en_US","og_type":"article","og_title":"Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference - Market Newsdesk","og_description":"WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) &#8212; Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that additional data supporting the efficacy and safety of IBSRELA will be presented in a poster at the 2023 Digestive Disease Week Conference (DDW 2023) to be held May 6-9, 2023, in Chicago, Illinois. Title: Analysis of Patient-Reported Treatment Satisfaction and Abdominal Pain Score in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) Treated with Tenapanor\u00a0 Authors:\u00a0\u00a0 Anthony Lembo, Darren M. Brenner, Brian E. Lacy, Suling Zhao, Susan Edelstein, David P. Rosenbaum Abstract Number: 3831977 Poster Number: Tu1618 Date\/Time:\u00a0\u00a0 May 9, 2023, from 12:30 PM &hellip; Continue reading \"Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-01T12:18:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODMyMSM1NTY0ODgxIzIwMDU0MDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference","datePublished":"2023-05-01T12:18:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/"},"wordCount":904,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODMyMSM1NTY0ODgxIzIwMDU0MDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/","name":"Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODMyMSM1NTY0ODgxIzIwMDU0MDg=","datePublished":"2023-05-01T12:18:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODMyMSM1NTY0ODgxIzIwMDU0MDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODMyMSM1NTY0ODgxIzIwMDU0MDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ardelyx-announces-additional-data-supporting-first-in-class-ibsrela-tenapanor-for-adults-with-ibs-c-to-be-presented-at-the-2023-digestive-disease-week-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA\u00ae (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=752944"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752944\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=752944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=752944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=752944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}